Plasmacytoid dendritic cells lead the charge against tumors.
Level V
Where this comes from
- Record sourced from PubMed, PMID 22251700.
- Also identified by DOI 10.1172/JCI61345 and PMC identifier 3266799.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.
Medical subject headings
- Adaptive Immunity
- Adjuvants, Immunologic
- Aminoquinolines
- Antineoplastic Agents
- Dendritic Cells
- Neoplasms, Experimental